Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma

Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma

Posterior reversible encephalopathy syndrome (PRES) is characterized by a group of central nervous system related symptoms. Diagnosis is usually made by computed tomography or magnetic resonance imaging. Common causes can be arterial hypertension, sepsis, autoimmune disorders, and medications. We re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of oncology pharmacy practice 2017-01, Vol.23 (1), p.71-74
Hauptverfasser: LaPorte, Justin, Solh, Melhem, Ouanounou, Serge
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents - therapeutic use
Female
Hodgkin Disease - drug therapy
Humans
Posterior Leukoencephalopathy Syndrome - drug therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 74
container_issue 1
container_start_page 71
container_title Journal of oncology pharmacy practice
container_volume 23
creator LaPorte, Justin
Solh, Melhem
Ouanounou, Serge
description Posterior reversible encephalopathy syndrome (PRES) is characterized by a group of central nervous system related symptoms. Diagnosis is usually made by computed tomography or magnetic resonance imaging. Common causes can be arterial hypertension, sepsis, autoimmune disorders, and medications. We report PRES in a relapsed Hodgkin’s Lymphoma patient after a dose of pembrolizumab.
doi_str_mv 10.1177/1078155215620922
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859495341</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1078155215620922</sage_id><sourcerecordid>4281455531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-e8e06ea87c776d61004fc34e392115a2e029797046458b692b4f68123c6e14c73</originalsourceid><addsrcrecordid>eNqNkU9r1kAQxpei9J_ePUnASy-pO5v9e5RibaFQDwrewiaZvG_qJht3k0o8-TX8ev0k3fC2RQqCpxl4fvMMMw8hb4CeAij1HqjSIAQDIRk1jO2RQ-BK5an_9iL1Sc5X_YAcxXhDKdWK6X1ywKQUAgAOyfDZxwlD50MW8BZD7CqHGQ41jlvr_Gin7ZLFZWiC7zFrvXP-ZzdsshH7KnjX_Zp7W2XTFoMdl6SvNs6OEZvswjeb791w9_tPzNzSj1vf21fkZWtdxNcP9Zh8Pf_45ewiv7r-dHn24SqvC6OnHDVSiVarWinZSKCUt3XBsTAMQFiGlBllFOWSC11JwyreSg2sqCUCr1VxTE52vmPwP2aMU9l3sUbn7IB-jiVoYbgRBYf_QNO3uDC6SOi7Z-iNn8OQDlkNKQVO-bqb7qg6-BgDtuUYut6GpQRarrGVz2NLI28fjOeqx-Zp4DGnBOQ7INoN_rX1X4b3GRygUQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1850014047</pqid></control><display><type>article</type><title>Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>LaPorte, Justin ; Solh, Melhem ; Ouanounou, Serge</creator><creatorcontrib>LaPorte, Justin ; Solh, Melhem ; Ouanounou, Serge</creatorcontrib><description>Posterior reversible encephalopathy syndrome (PRES) is characterized by a group of central nervous system related symptoms. Diagnosis is usually made by computed tomography or magnetic resonance imaging. Common causes can be arterial hypertension, sepsis, autoimmune disorders, and medications. We report PRES in a relapsed Hodgkin’s Lymphoma patient after a dose of pembrolizumab.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/1078155215620922</identifier><identifier>PMID: 26655111</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Agents - therapeutic use ; Female ; Hodgkin Disease - drug therapy ; Humans ; Posterior Leukoencephalopathy Syndrome - drug therapy</subject><ispartof>Journal of oncology pharmacy practice, 2017-01, Vol.23 (1), p.71-74</ispartof><rights>The Author(s) 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-e8e06ea87c776d61004fc34e392115a2e029797046458b692b4f68123c6e14c73</citedby><cites>FETCH-LOGICAL-c398t-e8e06ea87c776d61004fc34e392115a2e029797046458b692b4f68123c6e14c73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1078155215620922$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1078155215620922$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26655111$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LaPorte, Justin</creatorcontrib><creatorcontrib>Solh, Melhem</creatorcontrib><creatorcontrib>Ouanounou, Serge</creatorcontrib><title>Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Posterior reversible encephalopathy syndrome (PRES) is characterized by a group of central nervous system related symptoms. Diagnosis is usually made by computed tomography or magnetic resonance imaging. Common causes can be arterial hypertension, sepsis, autoimmune disorders, and medications. We report PRES in a relapsed Hodgkin’s Lymphoma patient after a dose of pembrolizumab.</description><subject>Adult</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Female</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Humans</subject><subject>Posterior Leukoencephalopathy Syndrome - drug therapy</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU9r1kAQxpei9J_ePUnASy-pO5v9e5RibaFQDwrewiaZvG_qJht3k0o8-TX8ev0k3fC2RQqCpxl4fvMMMw8hb4CeAij1HqjSIAQDIRk1jO2RQ-BK5an_9iL1Sc5X_YAcxXhDKdWK6X1ywKQUAgAOyfDZxwlD50MW8BZD7CqHGQ41jlvr_Gin7ZLFZWiC7zFrvXP-ZzdsshH7KnjX_Zp7W2XTFoMdl6SvNs6OEZvswjeb791w9_tPzNzSj1vf21fkZWtdxNcP9Zh8Pf_45ewiv7r-dHn24SqvC6OnHDVSiVarWinZSKCUt3XBsTAMQFiGlBllFOWSC11JwyreSg2sqCUCr1VxTE52vmPwP2aMU9l3sUbn7IB-jiVoYbgRBYf_QNO3uDC6SOi7Z-iNn8OQDlkNKQVO-bqb7qg6-BgDtuUYut6GpQRarrGVz2NLI28fjOeqx-Zp4DGnBOQ7INoN_rX1X4b3GRygUQ</recordid><startdate>201701</startdate><enddate>201701</enddate><creator>LaPorte, Justin</creator><creator>Solh, Melhem</creator><creator>Ouanounou, Serge</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201701</creationdate><title>Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma</title><author>LaPorte, Justin ; Solh, Melhem ; Ouanounou, Serge</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-e8e06ea87c776d61004fc34e392115a2e029797046458b692b4f68123c6e14c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Female</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Humans</topic><topic>Posterior Leukoencephalopathy Syndrome - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LaPorte, Justin</creatorcontrib><creatorcontrib>Solh, Melhem</creatorcontrib><creatorcontrib>Ouanounou, Serge</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LaPorte, Justin</au><au>Solh, Melhem</au><au>Ouanounou, Serge</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2017-01</date><risdate>2017</risdate><volume>23</volume><issue>1</issue><spage>71</spage><epage>74</epage><pages>71-74</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Posterior reversible encephalopathy syndrome (PRES) is characterized by a group of central nervous system related symptoms. Diagnosis is usually made by computed tomography or magnetic resonance imaging. Common causes can be arterial hypertension, sepsis, autoimmune disorders, and medications. We report PRES in a relapsed Hodgkin’s Lymphoma patient after a dose of pembrolizumab.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>26655111</pmid><doi>10.1177/1078155215620922</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1078-1552
ispartof Journal of oncology pharmacy practice, 2017-01, Vol.23 (1), p.71-74
issn 1078-1552
1477-092X
language eng
recordid cdi_proquest_miscellaneous_1859495341
source SAGE Complete A-Z List; MEDLINE
subjects Adult
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents - therapeutic use
Female
Hodgkin Disease - drug therapy
Humans
Posterior Leukoencephalopathy Syndrome - drug therapy
title Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T17%3A38%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Posterior%20reversible%20encephalopathy%20syndrome%20following%20pembrolizumab%20therapy%20for%20relapsed%20Hodgkin%E2%80%99s%20lymphoma&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=LaPorte,%20Justin&rft.date=2017-01&rft.volume=23&rft.issue=1&rft.spage=71&rft.epage=74&rft.pages=71-74&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/1078155215620922&rft_dat=%3Cproquest_cross%3E4281455531%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1850014047&rft_id=info:pmid/26655111&rft_sage_id=10.1177_1078155215620922&rfr_iscdi=true